长江商报奔腾新闻记者张璐 知名企业山鹰国际（600567）(600567.SH)向市场释放信心。 6月24日，山鹰国际公告，公司拟使用自有资金和自筹资金以集中竞价交易方式向社会公众股东回购公 司股份，本次回购股份的价格不超过2.50元/股，回购的资金总额不低于5亿元(含)且不超过10亿元(含)。 根据公告，按照本次回购资金总额的上、下限及回购价格上限2.50元/股计算，预计回购股份数量约为2 亿股-4亿股，约占公司目前已发行总股本3.6554%-7.3108% 回购往往为提振股价。长江商报奔腾新闻记者注意到，二级市场上，山鹰国际股价走势较平，今年以来 股价始终在1.6元/股—2元/股之间徘徊，截至6月24日其股价报收1.84元/股。山鹰国际本次回购价格上限 较现价高出35.87%，具有一定诚意。 对于此次回购股份的目的，山鹰国际表示，本次回购的股份将全部用于员工持股计划或股权激励。 2022年巨亏的罪魁祸首，是并购后遗症。2017年、2018年，山鹰国际先后以20亿元、19亿元、2.38亿元 高溢价收购北欧纸业、联盛纸业、凤凰纸业各100%股权，形成商誉33.18亿元。并购推动山鹰国际在 2017年、2018 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600293 证券简称：三峡新材公告编号：2025-026 湖北三峡新型建材股份有限公司关于上海证券交易所对公司2024年年度报告的信息披露监管工作函的回 复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，湖北三峡新型建材股份有限公司（以下简称"公司"）收到上海证券交易所出具的《关于湖北三峡 新型建材股份有限公司2024年年度报告的信息披露监管工作函》（上证公函【2025】0765号）（以下简 称"《监管工作函》"）。公司收到《监管工作函》后高度重视，对所列问题逐项核查。现就《监管工作 函》所列问题回复如下： 问题1：根据年报，公司实现营业收入17.33亿元，销售商品、提供劳务收到的现金10.14亿元，二者差异 较大且未在年报中说明上述差异情况。请公司：结合行业特征及公司实际经营情况，说明营业收入与销 售收到现金存在较大差异的原因及合理性。请年审会计师发表意见。 公司回复：公司营业收入与销售商品、提供劳务收到的现金的计算过程如下： 单位：万元 ■ 公司主要 ...

Core Viewpoint - The company, Guangdong Zhaoqing Xinghuo Biotechnology Co., Ltd. (Xinghuo Technology), has received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, particularly focusing on its cash flow from investment activities, which has shown continuous outflows over the past three years [1][2]. Investment Activities - The net cash flow from investment activities for the years 2022 to 2024 was -789 million, -859 million, and -864 million yuan respectively, indicating a consistent cash outflow [1]. - The cash payments for investments during the same period were 1.579 billion, 2.412 billion, and 1.8 billion yuan [1]. Major Investment Projects - The company has detailed its major investment projects, including the acquisition of 99.22% of Ningxia Yipin Biotechnology Co., Ltd. for a total transaction price of 5.376 billion yuan, with 4.585 billion yuan paid through share issuance and 791.6384 million yuan in cash [3][4]. - The decision to use self-owned funds for the cash payment of the acquisition was approved by the board of directors, adhering to the company's investment decision-making procedures [4]. Financial Performance - The company reported operating revenues of 1.601 billion, 1.606 billion, and 1.605 billion yuan for the years 2022 to 2024, with net profits attributable to the parent company of 120.579 million, 75.997 million, and 108.141 million yuan respectively [6]. - The net cash flow from operating activities increased from 211.975 million yuan in 2022 to 239.776 million yuan in 2024, indicating improved operational efficiency [19]. Cash Management and Investment Strategy - As of the end of 2024, the company had a cash balance of 1.759 billion yuan, a year-on-year increase of 23.97%, with interest income of 13 million yuan [9]. - The company has established a risk management system and a comprehensive financial management policy to control investment risks, including a clear approval process for investment products [8]. Debt and Financing - The company’s long-term borrowings stood at 1.721 billion yuan and short-term borrowings at 1.008 billion yuan at the end of 2024, with interest expenses of 110 million yuan [9]. - The company has been reducing its bank loan balance over the years, with a total bank borrowing of 3.391 billion yuan at the end of 2024, down from 4.188 billion yuan in 2022 [19]. Acquisition and Goodwill - The company acquired 100% of Sichuan Jiuling Pharmaceutical Technology Co., Ltd. in 2019, resulting in goodwill of 198 million yuan, which has been subject to impairment testing due to declining profitability in subsequent years [20][23].

上海姚记科技股份有限公司 www.lhratings.com 联合〔2025〕4257 号 联合资信评估股份有限公司通过对上海姚记科技股份有限公司 主体及其相关债券的信用状况进行跟踪分析和评估，确定维持上海 姚记科技股份有限公司主体长期信用等级为 A+，维持"姚记转债" 信用等级为 A+，评级展望为稳定。 特此公告 联合资信评估股份有限公司 评级总监： 二〇二五年六月二十四日 声 明 一、本报告是联合资信基于评级方法和评级程序得出的截至发表之日 的独立意见陈述，未受任何机构或个人影响。评级结论及相关分析为联合 资信基于相关信息和资料对评级对象所发表的前瞻性观点，而非对评级对 象的事实陈述或鉴证意见。联合资信有充分理由保证所出具的评级报告遵 循了真实、客观、公正的原则。鉴于信用评级工作特性及受客观条件影响， 本报告在资料信息获取、评级方法与模型、未来事项预测评估等方面存在 局限性。 二、本报告系联合资信接受上海姚记科技股份有限公司（以下简称 "该公司"）委托所出具，除因本次评级事项联合资信与该公司构成评级 委托关系外，联合资信、评级人员与该公司不存在任何影响评级行为独立、 客观、公正的关联关系。 三、本报告引用 ...

Transaction Overview - The company has completed the transfer of 8.40% shares of Shenyang Xinyuan Microelectronics Equipment Co., Ltd. (stock code 688037) from Shenyang Zhongke Tiansheng Automation Technology Co., Ltd. [1] - The share transfer agreement was signed on March 31, 2025, and the transfer was completed on May 29, 2025, with a total of 19,064,915 shares transferred [1]. Progress of the Transaction - As of June 23, 2025, the company holds a total of 35,964,665 shares in Xinyuan Micro, representing approximately 17.87% of its total share capital, making the company the largest shareholder [2]. - The company has nominated four non-independent directors and one independent director to the third board of Xinyuan Micro, achieving a majority in both categories [2]. Significance of Acquiring Control - The acquisition allows for synergistic effects between the company and Xinyuan Micro, as both operate in the integrated circuit equipment industry but with complementary product offerings [2]. - The collaboration is expected to enhance the integration of different equipment processes and improve competitiveness and shareholder returns through joint efforts in R&D, supply chain, and customer resources [2].

| 大信会计师事务所 WUYIGE Certified | | | | | | Public | | Accountants | LLP. | | 电话 | Telephone： | +86 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | （10）82330558 | | | | | | | | | | | | | | | 北京市海淀区知春路 1 号 Room2206 22/F,Xueyuan | | | | | | | | International | | Tower | | 传真 Fax： | | | +86（10）82327668 | | | | | | | | | | | | | | | 学院国际大厦 22 层 2206 No.1 ZhichunRoad,Haidian | | | | | | | Dist. | | | | 网址 | Internet： | | | www.daxincpa.com.cn | | | | | | | | | | | | | | | 10 ...

证券代码：600079 证券简称：人福医药 编号：临 2025-078 人福医药集团股份公司 关于 2024 年年度报告信息披露监管工作函的回复公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 人福医药集团股份公司（以下简称"人福医药"或"公司"）于近期收到上海证 券交易所发出的《关于人福医药集团股份公司2024年年度报告的信息披露监管工作函》 （上证公函【2025】0694号）（以下简称"《工作函》"）。公司收到《工作函》后 高度重视，立即组织相关人员对《工作函》所列问题逐项核查，现就《工作函》所列 问题回复如下： 除特别说明外，下文若出现各分项数值之和与总数尾数不符的情况，均为四舍五 入原因。 一、根据年报，本期公司实现营业收入 254.35 亿元，同比增长 3.71%，应收账 款期末余额 91.98 亿元，同比增加 13.36%，应收账款增速领先于营业收入。此外， 本期计提应收账款坏账准备 1.25 亿元，相较上年度增长 72%。按单项计提坏账准备 中，某一"非关联方"已"预计无法收回"，但计提比例 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 注：交易金额为不含税金额，往来余额为含税金额。 ②北汽华森2021-2024年前五大客户情况 单位：万元，币种：人民币 ■ 注：交易金额为不含税金额，往来余额为含税金额。 2、前五大供应商情况 ①廊坊京川2021-2024年前五大供应商情况 单位：万元，币种：人民币 ■ 回复： 1、商誉两年参数比对如下： ■ 2、商誉减值测试中盈利预测相关参数较前期发生较大调整的依据、原因及合理性如下： 注：交易金额为不含税金额，往来余额为含税金额。 ②北汽华森2021-2024年前五大供应商情况 ①廊坊京川主营业务为汽车零部件涂装，主要客户为安道拓以及延锋，该两家客户自2024年度起销售额 较2023年度销售额呈现下降趋势，安道拓同比下降约5%，延锋母公司华域汽车金属成型和模具同比下 降34.52%，因客户本身销售下滑，进而减少了对本公司之子公司廊坊京川汽车零部件涂装的需求，造 成廊坊京川营业收入自2024年起出现下降，同比减少12.35%。 ■ 问题（3）结合前述两家公司历史业绩情况、下游行业市场需求变化等，对比前期减值测试参数确定情 况、本期减值迹象产生的时点及原因 ...

提质升级，优化存量资产，将异辛烷和MTBE向下游加工成成品汽油，获取终端利润以减轻消费税造成 的负面影响，从而增强经营能力。 预计一期项目建成后首个完整会计年度达成50%产能，实现11.06亿元营业收入，0.15亿元净利润。完全 达产后，预计能够实现22.13亿元营业收入，0.35亿元净利润。 项目建设中，公司成品油调合设施采用国内先进集装式全自动调合装置，开发的调合软件和集散控制系 统（DCS）保证了产品调合的高效性和技术先进性。公司自主开发的成品油调合配方，结合企业自产产 品特点，汽柴油产品质量符合国家质量标准，具有经济性和市场竞争力。从项目设备和项目产品来看， 具备一定科创属性，通过本项目可以合理利用公司现有异辛烷、MTBE等产能，并减轻消费税造成的负 面影响，形成纵向一体化的产业链格局，有利于提升公司整体产业链科创属性，创造更好的经营效益。 五、关于在建工程与产能。2024年末，公司在建工程为6.37亿元，较上年增加28.14%。其中，重要在建 工程项目预算合计数为17.61亿元，期末余额为5.58亿元，其中部分项目工程进度超过100%暂未转为固 定资产。公司各主要项目产能均未满产，其中部分项目产能利 ...

Core Viewpoint - Zhejiang Xiangyuan Cultural Tourism Co., Ltd. (hereinafter referred to as "the Company") has responded to the Shanghai Stock Exchange's inquiry regarding its 2024 annual report, focusing on its business relationships with Shandong Meiheng and Shandong Rongrun, including sales figures and operational details [1][2]. Business Operations and Relationships - The Company has engaged in cloud communication business with Shandong Meiheng and Shandong Rongrun since 2019, with a gradual shift towards cultural tourism as its main business post-restructuring in 2022 [3][4]. - Sales figures for the cloud communication business from 2019 to 2024 show a decline in revenue contribution, with total revenue of 30.56 million yuan in 2024, accounting for 1.70% of the Company's total revenue [3][4]. - The Company’s main supplier, Shandong Rongrun, had a prepayment amount of 1.523 million yuan, while Shandong Meiheng was identified as a major customer with sales of 30.56 million yuan in 2024 [1][4]. Business Model and Processes - The cloud communication business model involves establishing a messaging platform that aggregates various SMS suppliers' capabilities, ensuring timely and efficient message delivery [5][6]. - The Company actively sought partnerships with major telecom operators and leveraged its existing resources to develop its cloud communication services, leading to a successful collaboration with Shandong Rongrun and Shandong Meiheng [5][6]. - The procurement process involves prepayment for SMS services, with a unit price of 0.02 yuan per SMS for a total of 100 million SMS purchased from Shandong Rongrun [10][11]. Financial Performance - The financial performance of the cloud communication business has shown fluctuations, with net profits ranging from -11.89 million yuan in 2020 to 33.53 million yuan in 2023, indicating a challenging yet evolving business landscape [3][4]. - The Company reported a total of 5.555 million yuan in revenue from its top five customers in the cloud communication sector for 2022, with Shandong Meiheng accounting for 50.25% of the total revenue [14][15]. Customer and Supplier Dynamics - The Company has established a clear distinction between its customers and suppliers, with Shandong Meiheng being a non-related party, ensuring transparency in its business dealings [14][15]. - The Company’s procurement strategy includes maintaining a stable SMS inventory through prepayments, which helps mitigate risks associated with supply chain disruptions [16][17].